Trial Profile
An Open Label, Dose Escalation, Safety and Pharmacokinetics Phase I Study With Cabazitaxel Administered as a 1-hour Intravenous Infusion Every 3 Weeks in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Prednisolone
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Sanofi; Sanofi K.K.
- 06 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 28 Oct 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014, as per ClinicalTrials.gov record.
- 28 Oct 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Dec 2014, as per ClinicalTrials.gov record.